SCHEMBL3555650

SCHEMBL3555650

CC(=CCc1ccc2cc3ccccc3cc2c1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.43
CYP2A6 P11509 1/20 0.41
PDPK1 O15530 1/20 0.40
TBXA2R P21731 1/20 0.40
PTGER4 P35408 1/20 0.40
PTGFR P43088 1/20 0.40
PTGER3 P43115 1/20 0.40
PTGER2 P43116 1/20 0.40
PTGDR Q13258 1/20 0.40
AKR1C3 P42330 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
CYP2C9 P11712 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SLC13A5 Q86YT5 1/20 0.38
ACHE P22303 1/20 0.38
NR1H4 Q96RI1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20204139 0.82 CYP1A2 (0.47) CYP1A2CYP2A6AKR1C3L3MBTL1
SCHEMBL30530 0.79 CYP2C9 (0.51) AKR1C3CYP2C9MEN1KMT2A
SCHEMBL30528 0.79 CYP2C9 (0.51) AKR1C3CYP2C9MEN1KMT2A
SCHEMBL3904718 0.79 ALOX5 (0.41) CYP1A2AKR1C3CYP2C9MEN1KMT2A
Iodide SCHEMBL3761279 0.78 CYP2C9 (0.50) AKR1C3CYP2C9MEN1KMT2A
SCHEMBL19097596 0.77 LMNA (0.55) AKR1C3CYP2C9KMT2A
SCHEMBL19097595 0.77 LMNA (0.55) AKR1C3CYP2C9KMT2A
SCHEMBL17940828 0.77 LMNA (0.48) AKR1C3L3MBTL1CYP2C9MEN1KMT2A
SCHEMBL480740 0.77 LMNA (0.48) AKR1C3L3MBTL1CYP2C9MEN1KMT2A
SCHEMBL17238780 0.76 FFAR1 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7663301-B2 for use as robust red organic phosphors GENERAL ELECTRIC COMPANY (US) 2010-02-16 US disclosed
WO-2006076247-A2 PHOSPHORESCENT FLUORENE, ANTHRACENE AND/OR THIOPHENE SUBSTITUTED METALLO- PORPHYRINS AND RELATED COMPOUNDS GENERAL ELECTRIC COMPANY (US) 2006-07-20 WO disclosed
US-20060152149-A1 Porphyrin compositions GENERAL ELECTRIC COMPANY (US) 2006-07-13 US disclosed
EP-0062611-B1 PHOTOPOLYMERISATION PROCESS CIBA-GEIGY AG (CH) 1985-04-24 EP disclosed
EP-0062611-A2 Photopolymerisation process CIBA-GEIGY AG (CH) 1982-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060152149-A1 Porphyrin compositions ACP1, MMS19, MVD CYP1A2 2696/4885CYP2A6 2252/4885PDPK1 2255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.